Hester Biosciences Peer Comparison

NSE: HESTERBIO | BSE: 524669

₹2,302.30

₹12.50 (0.55%)

As on 28-Aug-2026IST

Market cap

₹1,954 Cr

Revenue (TTM)

₹326 Cr

P/E Ratio

14.4

P/B Ratio

4.3

Div. Yield

0.5 %

Edit

	Hester Biosciences	Sequent Scientific	NGL Fine-Chem	Emcure Pharmaceuticals	Wockhardt
Market cap (₹ Cr)	1,954	11,757	1,737	35,497	32,104
Revenue (₹ Cr)	326	3,149	536	9,683	3,564
Net Profit (₹ Cr)	129.56	213.79	57.20	1,018.97	414.00
Net Margin (%)	38.70	6.70	10.35	10.47	11.23
RoE (%)	14.64	10.42	18.17	21.30	8.38
Price to Earnings	14.35	68.69	30.37	35.10	78.49
Price-To-Book	4.30	4.18	5.00	6.77	6.38

Income Statement (₹ Cr)

	Hester Biosciences	Sequent Scientific	NGL Fine-Chem	Emcure Pharmaceuticals	Wockhardt
Operating Revenue	332.60	3,420.31	500.95	7,896.00	3,373.00
Total Income	347.01	3,463.86	515.68	7,968.78	3,510.00
Total Expenditure	250.66	2,767.78	427.60	6,427.14	2,747.00
EBITDA	81.94	652.53	73.35	1,468.85	626.00
Depreciation	18.88	233.64	19.58	384.13	227.00
EBIT	63.06	418.89	53.77	1,084.73	399.00
Interest	10.93	69.21	5.13	175.78	213.00
Other Income	14.41	43.55	14.73	72.79	137.00
Exceptional Items	2.94	-44.21	--	-10.38	-85.00
Profit before Tax	75.84	349.03	63.37	971.35	238.00
Provision for Tax	18.35	124.37	15.24	263.88	39.00
Profit after Tax	57.48	224.65	48.13	707.47	199.00

	Hester Biosciences	Sequent Scientific	NGL Fine-Chem	Emcure Pharmaceuticals	Wockhardt
Shareholder's Funds	360.24	2,911.06	329.24	4,446.19	4,940.00
Minority Interest	7.55	203.67	--	195.37	341.00
Non-Current Liabilities	157.67	484.39	68.63	811.91	1,235.00
Current Liabilities	152.48	945.90	162.59	2,668.27	1,622.00
Total Liabilities	677.94	4,595.61	560.46	8,121.73	8,578.00

	Hester Biosciences	Sequent Scientific	NGL Fine-Chem	Emcure Pharmaceuticals	Wockhardt
Non-Current Assets	469.38	2,290.47	271.49	3,565.87	5,441.00
Current Assets	208.56	2,254.55	288.97	4,555.86	2,606.00
Total Assets	677.94	4,595.61	560.46	8,121.73	8,578.00
Total Debt*	188.26	435.81	122.50	730.70	2,125.00
Net Current Assets	56.08	1,308.65	126.38	1,887.59	984.00
Contingent Liabilities	--	26.69	0.80	393.94	768.26

	Hester Biosciences	Sequent Scientific	NGL Fine-Chem	Emcure Pharmaceuticals	Wockhardt
Cash From Operating Activities	64.14	322.91	43.32	851.71	390.00
Cash Flow from Investing Activities	-2.87	-84.12	-70.59	-94.00	-241.00
Cash from Financing Activities	-48.79	-123.33	29.55	-813.96	-54.00
Net Cash Inflow / Outflow	12.48	115.46	2.27	-56.25	95.00

	Hester Biosciences	Sequent Scientific	NGL Fine-Chem	Emcure Pharmaceuticals	Wockhardt
ROCE (%)	16.21	13.10	16.88	22.49	6.79
ROE (%)	17.05	9.06	15.74	19.19	4.29
ROA (%)	8.64	5.25	9.60	8.94	2.53
EBIT Margin (%)	28.97	20.35	17.58	19.52	22.62
Net Margin (%)	16.57	6.49	9.33	8.88	5.67
Cash Profit Margin (%)	22.95	13.40	13.52	13.61	10.98

	Hester Biosciences	Sequent Scientific	NGL Fine-Chem	Emcure Pharmaceuticals	Wockhardt
Revenue Growth (%)	6.91	13.75	36.03	18.59	11.99
EBIT Growth (%)	48.27	65.80	102.84	19.81	67.69
Net Profit Growth (%)	99.42	1,324.82	127.83	34.10	449.12
EPS Growth (%)	102.41	337.51	127.83	30.75	553.20
Book Value Growth (%)	14.63	20.14	16.57	50.94	13.47

	Hester Biosciences	Sequent Scientific	NGL Fine-Chem	Emcure Pharmaceuticals	Wockhardt
Price / Earnings	19.31	45.14	26.59	29.84	89.54
Price / Book Value	2.98	2.96	3.89	4.58	3.87
Dividend Yield (%)	0.87	0.00	0.08	0.28	0.00
EV/EBITDA	13.04	11.74	15.86	13.55	27.45
Market Cap (₹ Cr)	1,074.13	8,003.17	1,279.54	20,327.45	19,071.62

	Hester Biosciences	Sequent Scientific	NGL Fine-Chem	Emcure Pharmaceuticals	Wockhardt
Debt to Equity	0.52	0.16	0.37	0.16	0.43
Short term debt to equity ratio	0.07	0.04	0.16	0.11	0.09
Current Ratio	1.37	2.38	1.78	1.71	1.61
Quick Ratio	0.89	1.53	1.35	0.98	1.06
Interest Coverage	7.94	6.04	13.36	6.53	2.12

	Hester Biosciences	Sequent Scientific	NGL Fine-Chem	Emcure Pharmaceuticals	Wockhardt
Debtors to sales (%)	28.67	30.56	26.13	25.36	17.43
Asset Turnover	0.50	0.80	1.00	1.01	0.49
Receivable days	92.43	98.80	77.86	87.83	58.75
Inventory Days	78.37	79.26	44.28	78.64	75.82
Payable days	120.46	126.90	88.92	174.97	186.21
Cash Conversion Cycle	50.33	51.16	33.22	-8.50	-51.64

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.